Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy These Hot Cannabis Stocks Before It's Too Late?

By Keith Speights - Mar 2, 2021 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Not necessarily.

Enthusiasm over cannabis stocks has gone through lots of ups and downs over the past few years. It's safe to say that we're currently in another upswing. Pot stocks are hot once again.

Shares of three cannabis companies, in particular, skyrocketed more than 40% last month with even greater year-to-date gains. What are these hot cannabis stocks -- and should you buy them before it's too late?

Three cannabis leaves on a red line trending upward

Image source: Getty Images.

1. MedMen

MedMen Enterprises (MMNFF -9.64%) ranked as the best-performing cannabis stock in February with its shares more than tripling in value. So far this year, the retail cannabis stock is up over 250%.

This major move appears to be the result of a short squeeze that played out in a similar way as the Reddit-fueled rise of Sundial Growers (SNDL 20.05%). Both stocks spiked around the same time, and both experienced similar declines.


MMNFF data by YCharts

MedMen squeaked out quarter-over-quarter revenue growth in its second quarter, which ended on Dec. 26, 2020. However, it posted another big loss of $68.9 million.  

My personal opinion is that it's too late to ride the momentum for MedMen. I also think it's too soon to view the stock as a great long-term pick. MedMen continues to lose money and isn't on a clear path to profitability at this point.

2. RIV Capital

Shares of RIV Capital (CNPO.F 1.92%), formerly known as Canopy Rivers, vaulted 57% higher in February. The stock is now up more than 170% year to date.

The biggest news for RIV in February was the completion of the company's arrangement to transfer its stake in Terrascend to Canopy Growth (CGC 3.04%) in exchange for $115 million Canadian and shares of Canopy Growth worth around CA$170 million. This deal paves the way further for Canopy Growth, which spun off RIV Capital as a separate entity in 2019, to enter the U.S. market when federally permissible.

RIV Capital posted earnings of CA$1.4 million in its third quarter, which ended on Dec. 31, 2020. However, that profit was due to income tax recovery of CA$11.4 million. For now, RIV's financial position isn't one that makes the stock particularly attractive, in my view.

3. Aphria

Aphria (APHA) stands out as another high-flying pot stock in February, with its shares jumping nearly 43%. The stock is up close to 170% so far in 2021.

The company reported solid results for its second quarter, which ended Nov. 30, 2020. Aphria's revenue soared 33% year over year. The Canadian cannabis producer also delivered its seventh consecutive quarter of increasing positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). 

However, the primary underlying factor fueling Aphria's rise is the company's pending merger with Tilray (TLRY). Aphria is arguably becoming the biggest merger arbitrage play in the stock market. The combination of Aphria and Tilray will create the world's largest cannabis company based on revenue.

I'm not sold on Aphria as a top cannabis stock to buy, though. Bigger isn't always better. I'm also on the fence about the company's strategy for entering the U.S. cannabis market.

The most important point

If I had to choose one of these hot pot stocks, it would probably be Aphria. The company at least is consistently profitable. However, I don't think chasing the momentum with any of these stocks is advisable.

Marijuana decriminalization in the U.S. (which isn't the same as federal marijuana legalization but would allow states to enforce their own cannabis laws) could boost the fortunes of all three companies significantly. MedMen and RIV Capital could potentially list their shares on a major U.S. stock exchange, which could provide a nice catalyst. All three businesses would have increased growth prospects if marijuana is decriminalized in the U.S.

But I think there are other stocks that would be much bigger winners with major U.S. cannabis reform. And that brings me to the most important point of all: The hottest stocks right now won't necessarily be the hottest stocks over the long run. MedMen, RIV Capital, and Aphria are flying high. I believe that there are other cannabis stocks in a stronger position to fly even higher over the next few years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Stock Quote
Canopy Growth Stock Quote
Canopy Growth
$6.10 (3.04%) $0.18
MedMen Enterprises Stock Quote
MedMen Enterprises
$0.10 (-9.64%) $0.01
Tilray Stock Quote
RIV Capital Inc. Stock Quote
RIV Capital Inc.
$0.66 (1.92%) $0.01
TerrAscend Corp. Stock Quote
TerrAscend Corp.
$3.87 (-1.02%) $0.04
Sundial Growers Inc. Stock Quote
Sundial Growers Inc.
$0.46 (20.05%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.